BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

591 related articles for article (PubMed ID: 28294515)

  • 1. Clinical risk scoring for predicting non-alcoholic fatty liver disease in metabolic syndrome patients (NAFLD-MS score).
    Saokaew S; Kanchanasuwan S; Apisarnthanarak P; Charoensak A; Charatcharoenwitthaya P; Phisalprapa P; Chaiyakunapruk N
    Liver Int; 2017 Oct; 37(10):1535-1543. PubMed ID: 28294515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
    Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic value of alcoholic liver disease (ALD)/nonalcoholic fatty liver disease (NAFLD) index combined with γ-glutamyl transferase in differentiating ALD and NAFLD.
    Wang J; Li P; Jiang Z; Yang Q; Mi Y; Liu Y; Shi R; Zhou Y; Wang J; Lu W; Li S; Liu D
    Korean J Intern Med; 2016 May; 31(3):479-87. PubMed ID: 27025268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound.
    Petrović G; Bjelaković G; Benedeto-Stojanov D; Nagorni A; Brzački V; Marković-Živković B
    Vojnosanit Pregl; 2016 Oct; 73(10):910-20. PubMed ID: 29327896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NAFL screening score: A basic score identifying ultrasound-diagnosed non-alcoholic fatty liver.
    Zhou YJ; Zhou YF; Zheng JN; Liu WY; Van Poucke S; Zou TT; Zhang DC; Shen S; Shi KQ; Wang XD; Zheng MH
    Clin Chim Acta; 2017 Dec; 475():44-50. PubMed ID: 28964832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.
    McPherson S; Stewart SF; Henderson E; Burt AD; Day CP
    Gut; 2010 Sep; 59(9):1265-9. PubMed ID: 20801772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis.
    Ballestri S; Zona S; Targher G; Romagnoli D; Baldelli E; Nascimbeni F; Roverato A; Guaraldi G; Lonardo A
    J Gastroenterol Hepatol; 2016 May; 31(5):936-44. PubMed ID: 26667191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Non-alcoholic Fatty Liver Disease with Metabolic Syndrome Independently of Central Obesity and Insulin Resistance.
    Yang KC; Hung HF; Lu CW; Chang HH; Lee LT; Huang KC
    Sci Rep; 2016 Jun; 6():27034. PubMed ID: 27246655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of noninvasive scoring systems for the prediction of nonalcoholic fatty liver disease in metabolic syndrome patients.
    Saokaew S; Kositamongkol C; Charatcharoenwitthaya P; Srivanichakorn W; Washirasaksiri C; Chaiyakunapruk N; Phisalprapa P
    Medicine (Baltimore); 2020 Dec; 99(50):e23619. PubMed ID: 33327335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of non-invasive models of fibrosis in predicting mild to moderate fibrosis in patients with non-alcoholic fatty liver disease.
    Siddiqui MS; Patidar KR; Boyett S; Luketic VA; Puri P; Sanyal AJ
    Liver Int; 2016 Apr; 36(4):572-9. PubMed ID: 26713759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ZJU index: a novel model for predicting nonalcoholic fatty liver disease in a Chinese population.
    Wang J; Xu C; Xun Y; Lu Z; Shi J; Yu C; Li Y
    Sci Rep; 2015 Nov; 5():16494. PubMed ID: 26568423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between serum α-L-fucosidase and non-alcoholic fatty liver disease: Cross-sectional study.
    Lu ZY; Cen C; Shao Z; Chen XH; Xu CF; Li YM
    World J Gastroenterol; 2016 Feb; 22(5):1884-90. PubMed ID: 26855548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accuracy of Noninvasive Scoring Systems in Assessing Risk of Death and Liver-Related Endpoints in Patients With Nonalcoholic Fatty Liver Disease.
    Hagström H; Nasr P; Ekstedt M; Stål P; Hultcrantz R; Kechagias S
    Clin Gastroenterol Hepatol; 2019 May; 17(6):1148-1156.e4. PubMed ID: 30471458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fatty liver index vs waist circumference for predicting non-alcoholic fatty liver disease.
    Motamed N; Sohrabi M; Ajdarkosh H; Hemmasi G; Maadi M; Sayeedian FS; Pirzad R; Abedi K; Aghapour S; Fallahnezhad M; Zamani F
    World J Gastroenterol; 2016 Mar; 22(10):3023-30. PubMed ID: 26973398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of Aspartate Aminotranferase and Tumor Necrosis Factor-α as Non Invasive Diagnostic Tools for Non Alcoholic Steatohepatitis (NASH).
    Purnomo HD; Mundhofir FE; Kasno ; Sudijanto E; Darmono ; Daldiyono ; Djokomoeljanto R; Faradz SM
    Acta Med Indones; 2015 Jan; 47(1):16-23. PubMed ID: 25948763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of liver fibrosis using non-invasive screening tools in individuals with diabetes mellitus and metabolic syndrome.
    Shaji N; Singhai A; Joshi R
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simple scoring system for predicting cirrhosis in nonalcoholic fatty liver disease.
    Kessoku T; Ogawa Y; Yoneda M; Imajo K; Sumida Y; Eguchi Y; Fujii H; Hyogo H; Ono M; Suzuki Y; Kawaguchi T; Chayama K; Tanaka S; Fujimoto K; Anzai K; Saibara T; Sata M; Itoh Y; Nakajima A; Okanoue T;
    World J Gastroenterol; 2014 Aug; 20(29):10108-14. PubMed ID: 25110437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The association of non-alcoholic fatty liver disease and metabolic syndrome in a Chinese population.
    Lee SW; Lee TY; Yang SS; Peng YC; Yeh HZ; Chang CS
    Hepatobiliary Pancreat Dis Int; 2017 Apr; 16(2):176-180. PubMed ID: 28381382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High FIB-4 index as an independent risk factor of prevalent chronic kidney disease in patients with nonalcoholic fatty liver disease.
    Xu HW; Hsu YC; Chang CH; Wei KL; Lin CL
    Hepatol Int; 2016 Mar; 10(2):340-6. PubMed ID: 26676626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Score model for predicting acute-on-chronic liver failure risk in chronic hepatitis B.
    Gao FY; Liu Y; Li XS; Ye XQ; Sun L; Geng MF; Wang R; Liu HM; Zhou XB; Gu LL; Liu YM; Wan G; Wang XB
    World J Gastroenterol; 2015 Jul; 21(27):8373-81. PubMed ID: 26217089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.